Close
Achema middle east
swop processing & packaging

Evotec and Lilly enter into drug discovery collaboration in metabolic diseases

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

7 Most Important Contents in a Trauma Kit

Knowing what to include in a trauma kit is...

New Tariff Announcement by Trump for Pharma, Patented Drugs

The announcement made by President Donald Trump that his...

U.S. Tariff Relief for EU and Japan on Pharmaceuticals

Donald Trump’s new tariffs when it comes to pharmaceutical...

Five key considerations for biotechs outsourcing biologics manufacturing

Outsourcing is now critical for biotech companies aiming to...

Evotec SE announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company in the field of metabolic diseases with a focus on kidney diseases and diabetes.

The collaboration leverages Evotec’s extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention. Evotec will be responsible for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or by Evotec. Lilly reserves the right to select up to five programmes developed within this partnership and to continue with any subsequent development, clinical validation and commercialisation.

The collaboration initially runs for a term of three years. In addition to an undisclosed upfront payment, Evotec will be eligible to receive success-based discovery development, regulatory and commercial milestone payments of up to US$ 180 m per programme, as well as tiered royalties on net sales of any products resulting from the collaboration, for a potential overall value up to US$ 1 bn.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are excited to enter into this research partnership with Lilly. Over a period of several years, Evotec has systematically built a proprietary patient database by conducting multi-omics analyses of biospecimens from patient biobanks covering metabolic and kidney diseases. Evotec’s patient-derived molecular data in combination with our omics-supported multimodality drug discovery platform delivers highest quality drug candidates for our partners. We are proud to collaborate with Lilly in diabetes and kidney diseases as they are one of the leading companies in these areas.”

Latest stories

Related stories

7 Most Important Contents in a Trauma Kit

Knowing what to include in a trauma kit is...

New Tariff Announcement by Trump for Pharma, Patented Drugs

The announcement made by President Donald Trump that his...

U.S. Tariff Relief for EU and Japan on Pharmaceuticals

Donald Trump’s new tariffs when it comes to pharmaceutical...

Five key considerations for biotechs outsourcing biologics manufacturing

Outsourcing is now critical for biotech companies aiming to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »